Overall survival (OS) and time to progression (TTP). (A) OS by treatment response. Patients in complete remission (CR) and nodular partial response (PR-nod) had similarly favorable survival (6-year OS 88% and 77% respectively, P = .12). Survival for other categories was as follows: partial response due to incomplete recovery (PR-i), 6-year OS 42%; partial remission due to residual disease (PR-d), 5-year OS 24%; and resistant disease, 5-year OS 15%. (B) TTP by treatment response. Median TTP was longest in CR patients (85 months), followed by PR-nod and PR-i (71 months and 50 months, respectively), and was only 19 months for patients in PR-d. (C) Impact of flow cytometry (FL-C) status on TTP. Patients with less than 1% CD5/19 coexpressing cells in the bone marrow at the end of therapy had a significantly longer TTP (median 85 vs 49 months for FL-C negative vs positive, P < .001). (D) Impact of PCR status on TTP. PCR-negative patients had longer TTP than low positive patients (median 89 vs 80 months, respectively, P = .06), who in turn had longer TTP than PCR-positive patients (median 40 months, P = .001 compared with low positive patients).